You searched for "DMEK"
DSEK – five year results
This UK based study examined long-term descemet stripping endothelial keratoplasty (DSEK) results, looking at graft survival and endothelial cell losses. Data on 210 grafts were included in analysis. Most frequent indication for DSEK was Fuch’s endothelial dystrophy (81.4%) and 46.3%...
Ripasudil after Descemet stripping in Fuch’s endothelial dystrophy
This study prospectively evaluated the use of ripasudil, a rho kinase inhibitor, in patients undergoing Descemet’s stripping only (DSO) without an endothelial graft for Fuch’s endothelial dystrophy (FED). Patients with dense central guttae limited to the central 5mm of the...
RaScaL Study
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...Corneal dystrophies simplified
Based on biomicroscopic and histopathologic features, corneal dystrophies can be broadly classified into epithelial, Bowman’s layer / anterior stromal, stromal, and endothelial dystrophies. Corneal dystrophies are a group of inherited, bilateral, gradually progressing, non- inflammatory conditions caused by accumulation of...
Treatment of diabetic macular edema in vitrectomised eyes – comparison of intravitreal dexamethasone implant and posterior subtenon triamcinolone injection
This retrospective study was aimed to compare intravitreal dexamethasone implant and posterior subtenon triamcinolone injection (PSTA) in the treatment of diabetic macular edema (DME) in vitrectomised eyes. Sixty-four (48.12%) patients who had received PSTA and 69 (51.88%) patients who had...
Intravitreal dexamethasone implant for diabetic macular oedema
The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...In conversation with Christopher Liu OBE
Eye News caught up with Christopher Liu following his recent appointment by Her Majesty Queen Elizabeth II as an Officer of the Most Excellent Order of the British Empire for Services to Ophthalmology. Christopher Liu OBE. Congratulations on your recent...
Macular oedema after cataract surgery in diabetic patients
The authors describe a multi-centre prospective observational study of 293 participants that underwent cataract surgery who all had diabetic retinopathy without definite central-involved macular oedema. Forty-five clinical sites took part throughout the United States. Patients were eligible if there was...
VIBIM Study: One-year results of treatment of DME with aflibercept using TnE
The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...
OCTA in diabetic macular oedema treated with intravitreal aflibercept (DOCTA Study)
Central vision loss due to diabetic macular oedema (DME) can be attributed not only to presence of the macular oedema itself but also, in some cases, to alterations of the foveal avascular zone (FAZ). The DOCTA trial was a longitudinal,...
Systemic pharmacology of intravitreal anti-VEGF
This study aimed to evaluate and compare serum drug concentrations and plasma free-VEGF concentrations in patients with AMD, DME, or RVO receiving intravitreal injections of aflibercept, bevacizumab or ranibizumab. This prospective study enrolled patients from several offices of a single...
